Replies to post #35938 on Relief Therapeutics Holding AG (RLFTF)

[PennyWorld]

Actually, I just watched the recent video with Dr YO and JJ. JJ did a good job of explaining all of this, and the value of RLF100 going forward. Especially with the assessment that will take place at the 60 day point (Feb 20). So I'm very encouraged by JJ's explanation in that video. Patience is key with this one.

[soliloquy]

You mentioned the monitory end of the ICU and hospital stay but more importantly is being able to get the people home sooner to make room for others that need the ICU or hospital care. Very big deal ! I’d put up a rocket gif but that’s not my style LOL

[Inelgr]

"Don't put too much stock (no pun intended) into the 28 day mortality marker."

More on this from today's PR:

"The clinical trial was originally approved as a 28-day study at FDA's direction. In December, NeuroRx added a 60-day endpoint based on the recognition that the traditional 28-day endpoint adopted in the 1990s for trials in Acute Respiratory Distress Syndrome is not appropriate for critically ill patients with Covid-19, who are frequently maintained in the ICU with advanced technologies well beyond this time point. NeuroRx and other clinical trial sponsors alerted FDA to this trend and yesterday the FDA published formal guidance† changing the required time for measuring the prespecified endpoint of "alive and free of respiratory failure" in critically ill patients to 60 days. "

https://www.prnewswire.com/news-releases/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-19-treated-with-high-flow-nasal-oxygen-at-28-day-interim-endpoint-301233805.html



Earlier: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161750475

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161751085

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161753324